Cidara Therapeutics

Cidara Therapeutics

Cidara is a biotechnology company focused on treating severe and resistant microbial infections. Its lead product, Rezafungin (in a Phase III study for candidemia and invasive candidiasis), is from the echinocandin class of antifungals but is dosed as a once-weekly infusion, versus daily for the current echinocandins. This would provide the option of treating patients with the best antifungal on an outpatient basis, thus offering significant advantages to both patients and the healthcare system. Initial Phase II data have demonstrated a strong safety profile and confirmed the once-weekly dosing potential along with a favorable efficacy profile. Following a constructive meeting with the FDA, a smaller than expected Phase III study was possible allowing Cidara to also conduct a prophylaxis study in bone marrow transplant patients. The Phase III IC and candidemia study started in September 2018 with data expected in 2020. The company partnered with Mundipharma for all markets outside the US and Japan, which resulted in near-term funding for the Phase III program. Finally, Cidara is the only company developing an immunotherapy platform for serious infections with influenza as the first target.